Please use this identifier to cite or link to this item:
Title: Changes in the renin angiotensin system during the development of colorectal cancer liver metastases.
Austin Authors: Neo, Jaclyn H;Ager, Eleanor I;Angus, Peter W ;Zhu, Jin;Herath, Chandana B;Christophi, Christopher 
Affiliation: Department of Surgery, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 10-Apr-2010
Publication information: Bmc Cancer 2010; 10(): 134
Abstract: Blockade of the renin angiotensin system (RAS) via angiotensin I converting enzyme (ACE) inhibition reduces growth of colorectal cancer (CRC) liver metastases in a mouse model. In this work we defined the expression of the various components of the RAS in both tumor and liver during the progression of this disease.Immunohistochemistry and quantitative RT-PCR was used to examine RAS expression in a mouse CRC liver metastases model. CRC metastases and liver tissue was assessed separately at key stages of CRC liver metastases development in untreated (control) mice and in mice treated with the ACE inhibitor captopril (750 mg/kg/day). Non-tumor induced (sham) mice indicated the effect of tumors on normal liver RAS. The statistical significance of multiple comparisons was determined using one-way analysis of variance followed by Bonferroni adjustment with SAS/STAT software.Reduced volume of CRC liver metastases with captopril treatment was evident. Local RAS of CRC metastases differed from the surrounding liver, with lower angiotensin II type 1 receptor (AT1R) expression but increased ANG-(1-7) receptor (MasR) compared to the liver. The AT1R localised to cancer and stromal infiltrating cells, while other RAS receptors were detected in cancer cells only. Tumor induction led to an initial increase in AT1R and ACE expression while captopril treatment significantly increased ACE expression in the final stages of tumor growth. Conversely, captopril treatment decreased expression of AT1R and angiotensinogen.These results demonstrate significant changes in RAS expression in the tumor-bearing captopril treated liver and in CRC metastases. The data suggests the existence of a tumor-specific RAS that can be independently targeted by RAS blockade.
Gov't Doc #: 20380732
DOI: 10.1186/1471-2407-10-134
Type: Journal Article
Subjects: Angiotensin-Converting Enzyme Inhibitors.pharmacology
Colorectal Neoplasms.drug therapy.metabolism.pathology
Liver Neoplasms, Experimental.metabolism.prevention & control.secondary
Mice, Inbred CBA
Peptidyl-Dipeptidase A.biosynthesis
Receptor, Angiotensin, Type 1.biosynthesis
Receptor, Angiotensin, Type 2.biosynthesis
Renin-Angiotensin System.drug effects.physiology
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
20380732.pdf1.37 MBAdobe PDFThumbnail
Show full item record

Page view(s)

checked on Dec 1, 2022


checked on Dec 1, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.